Fearon E R, Pierceall W E
Department of Pathology, Boyer Center for Molecular Medicine, Yale University School of Medicine, New Haven, CT, USA.
Cancer Surv. 1995;24:3-17.
Chromosome 18q is among the regions thought to harbour a tumour suppressor gene(s) that is frequently inactivated by LOH during the development of several cancer types, including those of the gastrointestinal tract. In addition, colorectal cancers with 18q LOH have been shown to have a more aggressive clinical behaviour than those without 18q LOH. A candidate tumour suppressor gene from 18q, called DCC, has been identified. The DCC gene is contained within the common region of LOH on 18q, its expression is markedly decreased or absent in the majority of colorectal cancers and cell lines and somatic mutations within the DCC gene have been identified in a subset of cases. Thus, DCC represents the strongest candidate tumour suppressor gene on 18q. At present, however, many questions remain regarding the mechanisms underlying the inactivation of DCC and its decreased expression in cancers. The predicted structural similarity of DCC to the NCAMs suggests that it may function through cell-cell and/or cell-extracellular matrix interactions; however, little is known regarding the specific cellular function(s) of DCC. Many reports have detailed the alterations in phenotype observed in cancer cells, including changes in cell morphology and tissue architecture, loss of differentiated phenotype, decreased cell adhesion and aggregation, increased motility and invasive behaviour. These altered properties are likely to account in part for the invasive and metastatic properties of cancer cells in the patient. It is hoped that further studies will identify the means by which DCC inactivation may contribute to the altered growth properties of advanced cancer cells.
18号染色体长臂(18q)被认为是含有肿瘤抑制基因的区域之一,在包括胃肠道肿瘤在内的多种癌症发生过程中,该区域的肿瘤抑制基因常因杂合性缺失(LOH)而失活。此外,已证实具有18q杂合性缺失的结直肠癌比没有18q杂合性缺失的结直肠癌具有更具侵袭性的临床行为。已鉴定出一个位于18q的候选肿瘤抑制基因,称为DCC。DCC基因位于18q杂合性缺失的共同区域内,在大多数结直肠癌和细胞系中其表达明显降低或缺失,并且在一部分病例中已鉴定出DCC基因内的体细胞突变。因此,DCC是18q上最有力的候选肿瘤抑制基因。然而,目前关于DCC失活及其在癌症中表达降低的潜在机制仍存在许多问题。DCC与神经细胞黏附分子(NCAMs)预测的结构相似性表明,它可能通过细胞间和/或细胞与细胞外基质的相互作用发挥功能;然而,关于DCC的具体细胞功能知之甚少。许多报告详细描述了癌细胞中观察到的表型改变,包括细胞形态和组织结构的变化、分化表型的丧失、细胞黏附和聚集的减少、运动性和侵袭行为的增加。这些改变的特性可能部分解释了患者体内癌细胞的侵袭和转移特性。希望进一步的研究能够确定DCC失活可能导致晚期癌细胞生长特性改变的方式。